CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Veracyte Study Shows Decipher Test Predicts Abiraterone Benefit in Very High-Risk Prostate Cancer

By Public Technologies
  • Veracyte will present six genomic test studies at the ESMO Congress in Madrid, October 23-27, 2026.
  • Decipher Prostate findings will provide first evidence predicting benefit from adding abiraterone to androgen deprivation therapy in clinically very high-risk, nonmetastatic disease.
  • An October 25 presentation will examine the economics of Prosigna-guided chemotherapy decisions using two-year results from the Phase III OPTIMA breast cancer trial.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190800PRIMZONEFULLFEED9848165) on October 19, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk